COMPANY:

Owkin

"Owkin...and Proscia®...have announced a strategic partnership to streamline MSI testing for patients with colorectal cancer (CRC), the second most deadly cancer worldwide. As a first step in the collaboration, the companies will integrate Owkin’s MSIntuit CRC v2 with Proscia’s Concentriq software platform for studying its impact, and make it available as part of Proscia’s precision medicine AI portfolio to enable laboratories to keep pace with demand for MSI screening."

"Owkin...has announced MSIntuit CRC v21, a next-generation AI solution. Aimed at transforming the detection and treatment of colorectal cancer (CRC), MSIntuit CRC v2 will initially launch as an RUO version in the US on Roche’s navify Digital Pathology enterprise software. MSIntuit CRC v2 builds upon the success of the CE-IVD-certified MSIntuit CRC, integrating cutting-edge machine learning models developed by Owkin with Roche's unparalleled expertise in oncology diagnostics....This latest version features a new architecture with advanced machine learning models significantly enhancing model performance."

"Owkin...is pleased to announce a new partnership with AstraZeneca...to develop an AI-powered tool to pre-screen for gBRCA mutations (gBRCAm) in breast cancer directly from digitized pathology slides. As part of Owkin’s ongoing collaboration with Gustave Roussy and The Centre Léon Bérard through PortrAIt, a French consortium to accelerate precision medicine through AI-enabled digital pathology, this tool aims to significantly accelerate and expand access to gBRCA testing that too many patients may not be considered for."

"Owkin said...that it has expanded its artificial intelligence-enabled precision medicine platform to nine centers in Germany, Austria, and Switzerland...The research and drug-discovery partnerships will focus on prostate cancer, muscle-invasive bladder cancer (MIBC), and cardiovascular disease. For its part, Owkin will bring its BiomarkerPlus outcome prediction platform; its TargetMatch target discovery platform; and its TrialPlus clinical trial optimization platform."

"Aster Insights...and Owkin...are excited to announce a collaboration to accelerate key transatlantic research in breast cancer diagnostics...Aster Insights and Owkin are in the process of entering into a multi-year relationship with breast cancer designated as the first area of research focus."

"Owkin and University Hospitals Birmingham NHS Foundation Trust (UHB) announced...a new five year research partnership to use artificial intelligence (AI) to accelerate the screening and diagnosis of a range of diseases, starting with colorectal cancer...The first research project in this collaboration aims to evaluate the performance of Owkin’s MSIntuit CRC solution in the United Kingdom across UHB’s cohort of 830 patients with primary colorectal adenocarcinoma."

"...Owkin...announced it is working with Amazon Web Services (AWS) to transform drug discovery, de-risk and accelerate clinical trials, and develop AI diagnostics. Owkin will leverage AWS’s proven global infrastructure and secure, extensive and reliable cloud platform to enhance data operations, optimize for operational excellence, and drive forward research in precision medicine."

"Owkin and the team at Sorbonne University and Assistance Publique - Hôpitaux de Paris (AP-HP) are looking to change that by learning more about cancer patients, through artificial intelligence...The teams will focus initially on pancreatic cancer, a cancer that is frequently diagnosed at an advanced stage, thereby reducing the chances of recovery, since symptoms typically only appear after it has spread to other organs."

"Evotec SE...and Owkin...announced an A.I.-powered integrated multi-target collaboration in oncology, immunology and inflammation ('I&I')...The collaboration brings together highly complementary platforms and expertise to accurately select targets, discover and develop new therapeutics. Harmonising Owkin's cutting-edge target discovery engine with Evotec's end-to-end shared R&D platforms and disease biology expertise will accelerate Owkin's novel programmes from the discovery phase to the clinic."

"Owkin...and Cerba Path...announced a new partnership. The two companies will work together to integrate Owkin’s cutting-edge AI-driven diagnostics into Cerba Path’s routine digital workflows and further validate AI-based tools for precision medicine...This partnership between Owkin and Cerba Path will have Cerba Path deploy Owkin’s technology to enhance pathologists’ and clinicians’ ability to accelerate precision medicine and deliver better patient care. Owkin’s AI diagnostics will benefit from Cerba Path’s fully digitized workflow and be able to reach a broader audience of pathologists who can access the Cerba Path platform remotely from any location in France."

"Owkin...today announced that it has entered into a collaboration agreement with MSD, the trade name of Merck & Co Inc., Rahway NJ USA to develop and commercialize AI-powered digital pathology diagnostics for the EU market...This collaboration seeks to develop a pre-screening procedure to improve testing rates for MSI-H in endometrial, gastric, small intestinal, and biliary cancers. In these cancer types, MSI-H prevalence is low and MSI-H screening is not routinely performed. The collaboration will initially be focused in the European Union."

"Owkin...announced an integration with international medical imaging IT and cybersecurity company Sectra...to integrate Owkin’s MSIntuit® CRC AI diagnostic into Sectra’s digital pathology solution. MSIntuit® CRC is the first CE-marked AI diagnostic for microsatellite instability (MSI) testing for colorectal cancer using digital H&E slides. It serves as a pre-screening tool for colorectal cancer patients that aims to streamline MSI testing, saving critical pathology resources by significantly reducing the proportion of patients that need to be fully screened by traditional methods."

"In a peer-reviewed study published...a team of scientists from French-American techbio Owkin and pathology labs in France present a blind validation of MSIntuit™ CRC, a first-in-class AI-driven digital pathology diagnostic developed by Owkin, as a pre-screening tool aimed at optimizing the precision of diagnosis and treatment of colorectal cancer."

"Servier...and Owkin...announced an innovative partnership to use AI to advance and accelerate better-targeted therapies across multiple disease areas, including oncology...The two companies will initially tackle two major challenges within translational medicine and digital pathology."

"Owkin and Tribun Health announce a strategic partnership to advance the development and global deployment of Artificial Intelligence (AI) Diagnostic and Research solutions for pathology departments and pharma companies."

"Owkin has successfully achieved ISO 13845:2016 certification for the design, development, manufacturing and distribution of its transformational AI IVD diagnostic solutions. The reference standard, ISO 13845 provides stringent regulatory criteria that ensure quality throughout the lifecycle of a medical device; this certification highlights Owkin’s ability to deliver clinically robust solutions for unmet medical needs, developed with the highest quality and safety standards."

"Nature Communications...published PACpAInt – a cutting-edge AI model co-developed by Owkin and AP-HP that decodes the complexity of pancreatic cancer, potentially revolutionizing the diagnosis and treatment of a disease with the lowest survival rate of all common cancers...By being able to accurately predict tumor molecular subtypes and patient survival outcomes, and given the expansion of digital pathology worldwide, PACpAInt opens the way for patient stratification based on powerful molecular criteria in routine care and clinical trials."

"Owkin has successfully validated its MSIntuit™ CRC AI solution for colorectal cancer (CRC) screening, a major milestone in the use of AI to further improve precision diagnostics for the benefit of patients. The technology is now being integrated into clinical workflows via Medipath, France's largest network of pathologists."

"Owkin, Nanostring...and world-leading cancer research institutions University of Pittsburgh, Gustave Roussy, Lausanne University Hospital, Uniklinikum Erlangen/Friedrich-Alexander-Universität Erlangen-Nürnberg, and Charité - Universitätsmedizin Berlin are launching MOSAIC (Multi Omic Spatial Atlas In Cancer) at the American Society of Clinical Oncology’s annual meeting (booth #4037). MOSAIC is a landmark $50 million project to revolutionize cancer research through the use of spatial omics, a set of cutting-edge technologies that offer unprecedented information on the structure of tumors."

"AI Biotech Owkin...has received a letter of support from the European Medicines Agency (EMA) regarding their proposed statistical adjustment on deep learning prognosis covariates obtained from histological slides. The proposed method uses the predictions of two deep-learning models, MesoNet and HCCnet, as prognostic biomarkers for the adjustment of efficacy analysis on the overall survival of life-prolonging drugs in randomized phase 2 and phase 3 clinical trials."

"In research published in Nature Medicine today, AI biotech company Owkin has demonstrated for the first time that federated learning (FL) can be used to train deep learning models on data from multiple hospitals on histopathology data without the data leaving hospital firewalls...Using data kept within four leading French hospitals, Owkin built AI models that can accurately predict the future response of triple-negative breast cancer (TNBC) patients to neoadjuvant chemotherapy."

"Owkin...is collaborating with Stanford Medicine on research to improve the treatment of lung cancer and mesothelioma...Using Stanford Medicine’s multimodal patient data, including molecular data, the research aims to discover new biomarkers to improve the development of new treatments. It also aims to further the understanding of treatment-resistance mechanisms and identify potential treatment targets. Owkin, who is sponsoring the research, is contributing its expertise in AI to the study."

"Five ground-breaking artificial intelligence biology research abstracts led by AI biotech Owkin have been published by ESMO ahead of its 2022 Congress...The obtained results showed the ability of RlapsRisk to generalize on independent data and thus endorse the soundness of the method. Furthermore, additional analysis brings to light the clinical value of RlapsRisk and that it could be used for therapeutic de-escalation purposes."

"Artificial intelligence (AI) biotech company Owkin...announced that two first-in-class rapid, affordable AI-based diagnostic solutions designed to improve outcomes for patients with breast cancer and colorectal cancer have been approved for use in Europe...Owkin Dx RlapsRisk™ BC and Owkin Dx MSIntuit™ CRC have received CE-IVD approval for diagnostic use in the European Union. By using AI to analyze digital pathology images, they are designed to help clinicians make precision medicine – diagnostic and treatment based on a patient's individual characteristics – more accessible to more patients at an earlier stage of their disease."